A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory lymphoma. METHODS: Patients who failed pri...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Holen, Kyle D., Belani, Chandra P., Wilding, George, Ramalingam, Suresh, Volkman, Jennifer L., Ramanathan, Ramesh K., Vasist, Lakshmi S., Bowen, Carolyn J., Hodge, Jeffrey P., Dar, Mohammed M., Ho, Peter T. C.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160065/
https://ncbi.nlm.nih.gov/pubmed/20461380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1346-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares